A concise review of non-alcoholic fatty liver disease

Atherosclerosis

Volumn 239, Issue 1, 2015, Pages 192-202

  Than, Nwe Ni ^a   Newsome, Philip N ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cardiovascular disease; Dyslipidaemia; Insulin resistance; Non alcoholic fatty liver disease; Pathogenesis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTIOXIDANT; BETAINE; CYTOPROTECTIVE AGENT; FATTY ACID; INSULIN SENSITIZING AGENT; METFORMIN; PENTOXIFYLLINE; URSODEOXYCHOLIC ACID; TRIACYLGLYCEROL;

ADIPOSE TISSUE; BARIATRIC SURGERY; CARDIOVASCULAR RISK; DISEASE COURSE; GENETIC POLYMORPHISM; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE; LIVER; LIVER TRANSPLANTATION; META ANALYSIS (TOPIC); MICROBIOME; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WEIGHT REDUCTION; ADULT; APOPTOSIS; BLOOD; CARDIOVASCULAR DISEASE; CHILD; COMPLICATION; CYTOLOGY; DYSLIPIDEMIA; FATTY LIVER; FEMALE; FIBROSIS; LIVER CELL; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR;

ADIPOSE TISSUE; ADULT; APOPTOSIS; CARDIOVASCULAR DISEASES; CHILD; DYSLIPIDEMIAS; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; FEMALE; FIBROSIS; HEPATOCYTES; HUMANS; INSULIN RESISTANCE; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; POLYMORPHISM, GENETIC; RISK FACTORS; TRIGLYCERIDES;

EID: 84922622191     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.01.001     Document Type: Review

References (139)

1. Chalasani N., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55(6):2005-2023.
2. Dowman J.K., Tomlinson J.W., Newsome P.N. Pathogenesis of non-alcoholic fatty liver disease. Qjm 2010, 103(2):71-83.
3. Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance?. Hepatology 2010, 51(2):373-375.
4. Chang E., Park C.Y., Park S.W. Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. J.Diabetes Investig. 2013, 4(6):517-524.
5. Ahmed M.H., Barakat S., Almobarak A.O. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists?. J.Obes. 2012, 2012:483135.
6. Brea A., Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int. J. Cardiol. 2013, 167(4):1109-1117.
7. Targher G., Marra F., Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?. Diabetologia 2008, 51(11):1947-1953.
8. Armstrong M.J., et al. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014, 59(3):1174-1197.
9. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 2011, 34(3):274-285.
10. Wanless I.R., Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 12(5):1106-1110.
11. Williamson R.M., et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes Study. Diabetes Care 2011, 34(5):1139-1144.
12. Machado M., Marques-Vidal P., Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J.Hepatol. 2006, 45(4):600-606.
13. Gaggini M., et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013, 5(5):1544-1560.
14. Attar B.M., Van Thiel D.H. Current concepts and management approaches in nonalcoholic fatty liver disease. Sci. World J. 2013, 2013:481893.
15. Browning J.D., et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004, 40(6):1387-1395.
16. Bambha K., et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology 2012, 55(3):769-780.
17. Ekstedt M., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44(4):865-873.
18. Argo C.K., Al-Osaimi A.M., Caldwell S.H. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J.Hepatol. 2009, 51(2):371-379. http://www.ncbi.nlm.nih.gov/pubmed/?term=Northup%20PG%5BAuthor%5D%26cauthor=true%26cauthor_uid=19501928.
19. Perazzo H., et al. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia. Aliment. Pharmacol. Ther. 2014, 40(9):1081-1093.
20. Hamabe A., et al. Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period. J.Gastroenterol. 2011, 46(6):769-778.
21. Dunn W., Xu R., Schwimmer J.B. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008, 47(6):1947-1954.
22. Stanković M.N., et al. Time-dependent changes and association between liver free fatty acids, serum lipid profile and histological features in mice model of nonalcoholic fatty liver disease. Arch. Med. Res. 2014, 45(2):116-124.
23. Edens M.A., Kuipers F., Stolk R.P. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes. Rev. 2009, 10(4):412-419.
24. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N.Engl. J. Med. 2010, 363(14):1341-1350.
25. Treeprasertsuk S., Lopez-Jimenez F., Lindor K.D. Nonalcoholic fatty liver disease and the coronary artery disease. Dig. Dis. Sci. 2011, 56(1):35-45.
26. Day C.P., James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998, 114(4):842-845.
27. Hirosumi J., et al. Acentral role for JNK in obesity and insulin resistance. Nature 2002, 420(6913):333-336.
28. Cai D., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 2005, 11(2):183-190.
29. Del Ben M., et al. Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences. Intern Emerg. Med. 2012, 7(Suppl.3):S291-S296.
30. Marchesini G., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 1999, 107(5):450-455.
31. Biddinger S.B., et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell. Metab. 2008, 7(2):125-134.
32. Brown M.S., Goldstein J.L. Selective versus total insulin resistance: a pathogenic paradox. Cell. Metab. 2008, 7(2):95-96.
33. Rodriguez-Suarez E., et al. Non-alcoholic fatty liver disease proteomics. Proteomics Clin. Appl. 2010, 4(4):362-371.
34. Lim J.W., Dillon J., Miller M. Proteomic and genomic studies of non-alcoholic fatty liver disease-clues in the pathogenesis. World J. Gastroenterol. 2014, 20(26):8325-8340.
35. Ferre P., Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes. Metab. 2010, 12(Suppl.2):83-92.
36. Eissing L., et al. De novo lipogenesis in human fat and liver is linked to ChREBP-beta and metabolic health. Nat. Commun. 2013, 4:1528.
37. Wu M., et al. Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(13):5378-5383.
38. Shulman G.I. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N.Engl. J. Med. 2014, 371(12):1131-1141.
39. Loria P., Lonardo A., Targher G. Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. Clin. Sci. Lond. 2008, 115(1):1-12.
40. Schaffer J.E. Lipotoxicity: when tissues overeat. Curr. Opin. Lipidol. 2003, 14(3):281-287.
41. Kim J.K., et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(13):7522-7527.
42. Ferreira L.D., et al. Overexpressing human lipoprotein lipase in mouse skeletal muscle is associated with insulin resistance. Diabetes 2001, 50(5):1064-1068.
43. Bouwens L., et al. Quantitation, tissue distribution and proliferation kinetics of Kupffer cells in normal rat liver. Hepatology 1986, 6(4):718-722.
44. MacPhee P.J., Schmidt E.E., Groom A.C. Evidence for Kupffer cell migration along liver sinusoids, from high-resolution invivo microscopy. Am. J. Physiol. 1992, 263(1 Pt 1):G17-G23.
45. Rivera C.A., et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J.Hepatol. 2007, 47(4):571-579.
46. Stienstra R., et al. Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology 2010, 51(2):511-522.
47. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J.Hepatol. 2009, 51(1):212-223.
48. Park J.W., et al. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J.Gastroenterol. Hepatol. 2007, 22(4):491-497.
49. Ahima R.S., Flier J.S. Adipose tissue as an endocrine organ. Trends Endocrinol. Metab. 2000, 11(8):327-332.
50. Feldstein A.E., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125(2):437-443.
51. Feldstein A.E., et al. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J.Hepatol. 2003, 39(6):978-983.
52. Malhi H., Gores G.J. Cellular and molecular mechanisms of liver injury. Gastroenterology 2008, 134(6):1641-1654.
53. Dongiovanni P., et al. PNPLA3 I148M polymorphism and progressive liver disease. World J. Gastroenterol. 2013, 19(41):6969-6978.
54. Speliotes E.K., et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011, 7(3):e1001324.
55. Romeo S., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008, 40(12):1461-1465.
56. Kotronen A., et al. Acommon variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009, 52(6):1056-1060.
57. Sookoian S., Pirola C.J. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011, 53(6):1883-1894.
58. Chalasani N., et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 2010, 139(5):1567-1576. 1576.e1-6.
59. Santoro N., et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 2012, 55(3):781-789.
60. Fu D., et al. Genetic polymorphism of glucokinase on the risk of type 2 diabetes and impaired glucose regulation: evidence based on 298,468 subjects. PLoS One 2013, 8(2):e55727.
61. Ferolla S.M., et al. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients 2014, 6(12):5583-5599.
62. Duseja A., Chawla Y.K. Obesity and NAFLD: the role of bacteria and microbiota. Clin. Liver Dis. 2014, 18(1):59-71.
63. Eslamparast T., et al. Probiotics and nonalcoholic fatty liver disease. Middle East J. Dig. Dis. 2013, 5(3):129-136.
64. Baldwin A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev. Immunol. 1996, 14:649-683.
65. Henao-Mejia J., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482(7384):179-185.
66. Mouzaki M., et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013, 58(1):120-127.
67. Jiang C., et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J.Clin. Invest 2014.
68. Ballestri S., et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J. Gastroenterol. 2014, 20(7):1724-1745.
69. Ndumele C.E., et al. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler. Thromb. Vasc. Biol. 2011, 31(8):1927-1932.
70. Verrijken A., et al. Prothrombotic factors in histologically proven NAFLD and NASH. Hepatology 2013, 59:121-129.
71. Yoneda M., et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J.Gastroenterol. 2007, 42(7):573-582.
72. Puchner S.B., et al. High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and Stenosis Burden: results from the ROMICAT II trial. Radiology 2014, 140933.
73. Ekstedt M., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2014, (Epub ahead of print). 10.1002/hep.27368.
74. Dongiovanni P., et al. TM6SF2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2014, (Epub ahead of print). 10.1002/hep.27490.
75. Targher G., et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006, 29(6):1325-1330.
76. Colak Y., et al. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine 2013, 43(1):100-107.
77. Chen C.H., et al. Association between nonalcoholic fatty liver disease and coronary artery calcification. Dig. Dis. Sci. 2010, 55(6):1752-1760.
78. Sirota J.C., et al. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism 2013, 62(3):392-399.
79. Nakagawa T., et al. SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 2009, 137(3):560-570.
80. Johnson R.J., et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes 2013, 62(10):3307-3315.
81. Speliotes E.K., et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010, 51(6):1979-1987.
82. Bugianesi E., et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005, 48(4):634-642.
83. Choe Y.G., et al. Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects. J.Gastroenterol. Hepatol. 2013, 28(4):678-683.
84. Maurantonio M., et al. Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?. Arch. Med. Res. 2011, 42(5):337-353.
85. Armstrong M.J., et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J.Hepatol. 2012, 56(1):234-240.
86. Wong V.W., et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012, 61(3):409-415.
87. Dyson J.K., Anstee Q.M., McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 2014, 5(3):211-218.
88. Verma S., et al. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. 2013, 33(9):1398-1405.
89. Karlas T., et al. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One 2014, 9(3):e91987.
90. de Ledinghen V., et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J.Hepatol. 2014, 60(5):1026-1031.
91. Banerjee R., et al. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J.Hepatol. 2014, 60(1):69-77.
92. Leitao H.S., et al. MR fat fraction mapping: a simple biomarker for liver steatosis quantification in nonalcoholic fatty liver disease patients. Acad. Radiol. 2013, 20(8):957-961.
93. McPherson S., et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010, 59(9):1265-1269.
94. Dowman J.K., Tomlinson J.W., Newsome P.N. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2011, 33(5):525-540.
95. Sanyal A.J., et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011, 54(1):344-353.
96. Martín-Domínguez Verónica, G.-C.R., Mendoza-Jiménez-Ridruejo J., García-Buey Luisa, Moreno-Otero Ricardo Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease. Rev. Esp. Enferm. Dig. 2013, 105:409-420.
97. Shah K., et al. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity (Silver Spring) 2009, 17(12):2162-2168.
98. Palmer M., Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990, 99(5):1408-1413.
99. Yancy W.S., et al. Alow-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann. Intern Med. 2004, 140(10):769-777.
100. Promrat K., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51(1):121-129.
101. Oh S., et al. Moderate to vigorous physical activity volume is an important factor for managing non-alcoholic fatty liver disease: a retrospective study. Hepatology 2014, (Epub ahead of print). 10.1002/hep.27544.
102. Zelber-Sagi S., et al. Adouble-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2006, 4(5):639-644.
103. Bray G.A., et al. Adouble-blind randomized placebo-controlled trial of sibutramine. Obes. Res. 1996, 4(3):263-270.
104. James W.P., et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000, 356(9248):2119-2125.
105. Dowman J.K., et al. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes Obes. Metab. 2011, 13(8):692-702.
106. James W.P., et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N.Engl. J. Med. 2010, 363(10):905-917.
107. Scheen A.J., et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006, 368(9548):1660-1672.
108. Pi-Sunyer F.X., et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295(7):761-775.
109. Van Gaal L.F., et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365(9468):1389-1397.
110. Topol E.J., et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 2010, 376(9740):517-523.
111. Mummadi R.R., et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2008, 6(12):1396-1402.
112. Zhou G., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J.Clin. Invest 2001, 108(8):1167-1174.
113. Coughlan K.A., et al. AMPK activation: a therapeutic target for type 2 diabetes?. Diabetes Metab. Syndr. Obes. 2014, 7:241-253.
114. Li Y., et al. Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Biomed. Rep. 2013, 1(1):57-64.
115. Musso G., et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012, 55(4):885-904.
116. Zanchi A., et al. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J.Clin. Endocrinol. Metab. 2004, 89(3):1140-1145.
117. Singh S., Loke Y.K., Furberg C.D. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007, 30(8):2148-2153.
118. Belfort R., et al. Aplacebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N.Engl. J. Med. 2006, 355(22):2297-2307.
119. Sanyal A.J., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N.Engl. J. Med. 2010, 362(18):1675-1685.
120. Rask E., et al. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 2001, 24(9):1640-1645.
121. Vilsboll T., et al. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul. Pept. 2003, 114(2-3):115-121.
122. Blaslov K., et al. Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. World J. Gastroenterol. 2014, 20(23):7356-7365.
123. Vilsboll T., et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007, 30(6):1608-1610.
124. Kolterman O.G., et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J.Clin. Endocrinol. Metab. 2003, 88(7):3082-3089.
125. Fukuhara T., et al. Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. Hepatogastroenterology 2014, 61(130):323-328.
126. Aschner P., et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29(12):2632-2637.
127. Rosenstock J., et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr. Med. Res. Opin. 2009, 25(10):2401-2411.
128. Buse J.B., et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin. Ther. 2007, 29(1):139-153.
129. Lavine J.E., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011, 305(16):1659-1668.
130. Beaton M.D. Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Can. J. Gastroenterol. 2012, 26(6):353-357.
131. Abdelmalek M.F., et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009, 50(6):1818-1826.
132. Leuschner U.F., et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010, 52(2):472-479.
133. Lindor K.D., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39(3):770-778.
134. Zeng T., et al. Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies. Eur. J. Gastroenterol. Hepatol. 2014, 26(6):646-653.
135. Paolella G., et al. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J. Gastroenterol. 2014, 20(42):15518-15531.
136. Ma Y.Y., et al. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J. Gastroenterol. 2013, 19(40):6911-6918.
137. Alisi A., et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2014, 39(11):1276-1285.
138. Malaguarnera M., et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig. Dis. Sci. 2012, 57(2):545-553.
139. Newsome P.N., et al. Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. Gut 2012, 61(4):484-500.